Selected research
Market Structure
Global Kidney Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Kidney Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Kidney Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Kidney Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Kidney Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Kidney Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Kidney Cancer include Aveo Pharmaceuticals, Bristol-Myers Squibb, Exelixis, Hikma Pharmaceuticals, Sun Pharmaceutical, Amgen, Bayer, Pfizer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Kidney Cancer market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Kidney Cancer and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Kidney Cancer revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Kidney Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.
Kidney Cancer Segment by Company
Aveo Pharmaceuticals
Bristol-Myers Squibb
Exelixis
Hikma Pharmaceuticals
Sun Pharmaceutical
Amgen
Bayer
Pfizer
Roche
Merck
Novartis
Eisai
Kidney Cancer Segment by Type
Targeted Therapy
Immunotherapy
Surgery
Other
Kidney Cancer Segment by Application
Renal Cell Carcinoma
Renal Pelvis Cancer
Other
Kidney Cancer Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Kidney Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Kidney Cancer industry.
Chapter 3: Detailed analysis of Kidney Cancer companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney Cancerrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Targeted Therapy
- Immunotherapy
- Surgery
- Other
Applications
- Renal Cell Carcinoma
- Renal Pelvis Cancer
- Other
Companies covered
- Aveo Pharmaceuticals
- Bristol-Myers Squibb
- Exelixis
- Hikma Pharmaceuticals
- Sun Pharmaceutical
- Amgen
- Bayer
- Pfizer
- Roche
- Merck
- Novartis
- Eisai
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Kidney Cancer Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Targeted Therapy
- 1.2.3 Immunotherapy
- 1.2.4 Surgery
- 1.2.5 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Kidney Cancer Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Renal Cell Carcinoma
- 1.3.3 Renal Pelvis Cancer
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Kidney Cancer Growth Trends by Region
- 1.5.1 Global Kidney Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Kidney Cancer Market Size by Region (2021-2026)
- 1.5.3 Kidney Cancer Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Kidney Cancer Market Dynamics
- 2.1 Kidney Cancer Industry Trends
- 2.2 Kidney Cancer Industry Drivers
- 2.3 Kidney Cancer Industry Opportunities and Challenges
- 2.4 Kidney Cancer Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Kidney Cancer Revenue by Company (2021-2026)
- 3.2 Global Kidney Cancer Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Kidney Cancer Key Company Head office and Area Served
- 3.4 Global Kidney Cancer Company, Product Type & Application
- 3.5 Global Kidney Cancer Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Kidney Cancer Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Kidney Cancer Players Market Share by Revenue in 2025
- 3.6.3 2025 Kidney Cancer Tier 1, Tier 2, and Tier 3
4 Kidney Cancer Market by Type
- 4.1 Global Kidney Cancer Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Kidney Cancer Market Size by Type (2021-2032)
- 4.3 Global Kidney Cancer Market Size Share by Type (2021-2032)
5 Kidney Cancer Market by Application
- 5.1 Global Kidney Cancer Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Kidney Cancer Market Size by Application (2021-2032)
- 5.3 Global Kidney Cancer Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Aveo Pharmaceuticals
- 6.1.1 Aveo Pharmaceuticals Company Information
- 6.1.2 Aveo Pharmaceuticals Business Overview
- 6.1.3 Aveo Pharmaceuticals Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Aveo Pharmaceuticals Kidney Cancer Product Portfolio
- 6.1.5 Aveo Pharmaceuticals Recent Developments
- 6.2 Bristol-Myers Squibb
- 6.2.1 Bristol-Myers Squibb Company Information
- 6.2.2 Bristol-Myers Squibb Business Overview
- 6.2.3 Bristol-Myers Squibb Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Bristol-Myers Squibb Kidney Cancer Product Portfolio
- 6.2.5 Bristol-Myers Squibb Recent Developments
- 6.3 Exelixis
- 6.3.1 Exelixis Company Information
- 6.3.2 Exelixis Business Overview
- 6.3.3 Exelixis Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Exelixis Kidney Cancer Product Portfolio
- 6.3.5 Exelixis Recent Developments
- 6.4 Hikma Pharmaceuticals
- 6.4.1 Hikma Pharmaceuticals Company Information
- 6.4.2 Hikma Pharmaceuticals Business Overview
- 6.4.3 Hikma Pharmaceuticals Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Hikma Pharmaceuticals Kidney Cancer Product Portfolio
- 6.4.5 Hikma Pharmaceuticals Recent Developments
- 6.5 Sun Pharmaceutical
- 6.5.1 Sun Pharmaceutical Company Information
- 6.5.2 Sun Pharmaceutical Business Overview
- 6.5.3 Sun Pharmaceutical Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Sun Pharmaceutical Kidney Cancer Product Portfolio
- 6.5.5 Sun Pharmaceutical Recent Developments
- 6.6 Amgen
- 6.6.1 Amgen Company Information
- 6.6.2 Amgen Business Overview
- 6.6.3 Amgen Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Amgen Kidney Cancer Product Portfolio
- 6.6.5 Amgen Recent Developments
- 6.7 Bayer
- 6.7.1 Bayer Company Information
- 6.7.2 Bayer Business Overview
- 6.7.3 Bayer Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Bayer Kidney Cancer Product Portfolio
- 6.7.5 Bayer Recent Developments
- 6.8 Pfizer
- 6.8.1 Pfizer Company Information
- 6.8.2 Pfizer Business Overview
- 6.8.3 Pfizer Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Pfizer Kidney Cancer Product Portfolio
- 6.8.5 Pfizer Recent Developments
- 6.9 Roche
- 6.9.1 Roche Company Information
- 6.9.2 Roche Business Overview
- 6.9.3 Roche Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Roche Kidney Cancer Product Portfolio
- 6.9.5 Roche Recent Developments
- 6.10 Merck
- 6.10.1 Merck Company Information
- 6.10.2 Merck Business Overview
- 6.10.3 Merck Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Merck Kidney Cancer Product Portfolio
- 6.10.5 Merck Recent Developments
- 6.11 Novartis
- 6.11.1 Novartis Company Information
- 6.11.2 Novartis Business Overview
- 6.11.3 Novartis Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Novartis Kidney Cancer Product Portfolio
- 6.11.5 Novartis Recent Developments
- 6.12 Eisai
- 6.12.1 Eisai Company Information
- 6.12.2 Eisai Business Overview
- 6.12.3 Eisai Kidney Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Eisai Kidney Cancer Product Portfolio
- 6.12.5 Eisai Recent Developments
7 North America
- 7.1 North America Kidney Cancer Market Size (2021-2032)
- 7.2 North America Kidney Cancer Market Size by Type
- 7.2.1 North America Kidney Cancer Market Size by Type (2021-2026)
- 7.2.2 North America Kidney Cancer Market Size by Type (2027-2032)
- 7.2.3 North America Kidney Cancer Market Share by Type (2021-2032)
- 7.3 North America Kidney Cancer Market Size by Application
- 7.3.1 North America Kidney Cancer Market Size by Application (2021-2026)
- 7.3.2 North America Kidney Cancer Market Size by Application (2027-2032)
- 7.3.3 North America Kidney Cancer Market Share by Application (2021-2032)
- 7.4 North America Kidney Cancer Market Size by Country
- 7.4.1 North America Kidney Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Kidney Cancer Market Size by Country (2021-2026)
- 7.4.3 North America Kidney Cancer Market Size by Country (2027-2032)
- 7.4.4 North America Kidney Cancer Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Kidney Cancer Market Size (2021-2032)
- 8.2 Europe Kidney Cancer Market Size by Type
- 8.2.1 Europe Kidney Cancer Market Size by Type (2021-2026)
- 8.2.2 Europe Kidney Cancer Market Size by Type (2027-2032)
- 8.2.3 Europe Kidney Cancer Market Share by Type (2021-2032)
- 8.3 Europe Kidney Cancer Market Size by Application
- 8.3.1 Europe Kidney Cancer Market Size by Application (2021-2026)
- 8.3.2 Europe Kidney Cancer Market Size by Application (2027-2032)
- 8.3.3 Europe Kidney Cancer Market Share by Application (2021-2032)
- 8.4 Europe Kidney Cancer Market Size by Country
- 8.4.1 Europe Kidney Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Kidney Cancer Market Size by Country (2021-2026)
- 8.4.3 Europe Kidney Cancer Market Size by Country (2027-2032)
- 8.4.4 Europe Kidney Cancer Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Kidney Cancer Market Size (2021-2032)
- 9.2 China Kidney Cancer Market Size by Type
- 9.2.1 China Kidney Cancer Market Size by Type (2021-2026)
- 9.2.2 China Kidney Cancer Market Size by Type (2027-2032)
- 9.2.3 China Kidney Cancer Market Share by Type (2021-2032)
- 9.3 China Kidney Cancer Market Size by Application
- 9.3.1 China Kidney Cancer Market Size by Application (2021-2026)
- 9.3.2 China Kidney Cancer Market Size by Application (2027-2032)
- 9.3.3 China Kidney Cancer Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Kidney Cancer Market Size (2021-2032)
- 10.2 Asia Kidney Cancer Market Size by Type
- 10.2.1 Asia Kidney Cancer Market Size by Type (2021-2026)
- 10.2.2 Asia Kidney Cancer Market Size by Type (2027-2032)
- 10.2.3 Asia Kidney Cancer Market Share by Type (2021-2032)
- 10.3 Asia Kidney Cancer Market Size by Application
- 10.3.1 Asia Kidney Cancer Market Size by Application (2021-2026)
- 10.3.2 Asia Kidney Cancer Market Size by Application (2027-2032)
- 10.3.3 Asia Kidney Cancer Market Share by Application (2021-2032)
- 10.4 Asia Kidney Cancer Market Size by Country
- 10.4.1 Asia Kidney Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Kidney Cancer Market Size by Country (2021-2026)
- 10.4.3 Asia Kidney Cancer Market Size by Country (2027-2032)
- 10.4.4 Asia Kidney Cancer Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Kidney Cancer Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Kidney Cancer Market Size by Type
- 11.2.1 South America, Middle East & Africa Kidney Cancer Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Kidney Cancer Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Kidney Cancer Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Kidney Cancer Market Size by Application
- 11.3.1 South America, Middle East & Africa Kidney Cancer Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Kidney Cancer Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Kidney Cancer Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Kidney Cancer Market Size by Country
- 11.4.1 South America, Middle East & Africa Kidney Cancer Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Kidney Cancer Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Kidney Cancer Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Kidney Cancer Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst